Although colchicine has been used for centuries, its neuromuscular toxicity in humans is largely unrecognized. In this report we describe a characteristic syndrome of myopathy and neuropathy and present 12 new cases of the condition. Colchicine myopathy may occur in patients with gout who take customary doses of the drug but who have elevated plasma drug levels because of altered renal function. It usually presents with proximal weakness and always presents with elevation of serum creatine kinase; both features remit within three to four weeks after the drug is discontinued. The accompanying axonal polyneuropathy is mild and resolves slowly. Electromyography of proximal muscles shows a myopathy that is marked by abnormal spontaneous activity. Because of these features, colchicine myoneuropathy is usually misdiagnosed initially, either as probable polymyositis or as uremic neuropathy. The myopathy is vacuolar, marked by accumulation of lysosomes and autophagic vacuoles unrelated to necrosis or to the mild denervation in distal muscles. The morphologic changes in muscle suggest that the pathogenesis involves disruption of a microtubule-dependent cytoskeletal network that interacts with lysosomes. Correct diagnosis may save patients with this disorder from inappropriate therapy.
This article has been cited by other articles:
Kallinich, T., Haffner, D., Niehues, T., Huss, K., Lainka, E., Neudorf, U., Schaefer, C., Stojanov, S., Timmann, C., Keitzer, R., Ozdogan, H., Ozen, S.
(2007). Colchicine Use in Children and Adolescents With Familial Mediterranean Fever: Literature Review and Consensus Statement. Pediatrics
119: e474-e483
[Abstract][Full Text]
Lustberg, M. E., Gelber, A. C., Becker, M. A., Palo, W. A., Joseph-Ridge, N.
(2006). Febuxostat versus allopurinol for gout.. NEJM
354: 1532-1533
[Full Text]
Troger, U., Lins, H., Scherrmann, J.-M, Wallesch, C.-W., Bode-Boger, S. M
(2005). Tetraparesis associated with colchicine is probably due to inhibition by verapamil of the P-glycoprotein efflux pump in the blood-brain barrier. BMJ
331: 613-613
[Full Text]
Suresh, E
(2005). Diagnosis and management of gout: a rational approach. Postgrad. Med. J.
81: 572-579
[Abstract][Full Text]
Sayarlioglu, M., Sayarlioglu, H., Ozen, S., Erkoc, R., Gul, A.
(2003). Colchicine-Induced Myopathy in a Teenager with Familial Mediterranean Fever. The Annals of Pharmacotherapy
37: 1821-1824
[Abstract][Full Text]
Soto, O., Hedley-Whyte, E. T.
(2003). Case 33-2003 - A 37-Year-Old Man with a History of Alcohol and Drug Abuse and Sudden Onset of Leg Weakness. NEJM
349: 1656-1663
[Full Text]
Chattopadhyay, I, Shetty, H G M, Routledge, P A, Jeffery, J
(2001). Colchicine induced rhabdomyolysis. Postgrad. Med. J.
77: 191-192
[Abstract][Full Text]
Aksu, K., Keser, G., Gunaydin, G., Ozbek, S. S., Colakoglu, Z., Gumusdis, G., Doganavsargil, E.
(2000). Erectile dysfunction in Behcet's disease without neurological involvement: two case reports. Rheumatology (Oxford)
39: 1429-1431
[Full Text]
Shinde, A., Nakano, S., Abe, M., Kohara, N., Akiguchi, I., Shibasaki, H.
(2000). Accumulation of microtubule-based motor protein in a patient with colchicine myopathy. Neurology
55: 1414-1415
[Full Text]
CLIVE, D. M.
(2000). Renal Transplant-Associated Hyperuricemia and Gout. J. Am. Soc. Nephrol.
11: 974-979
[Full Text]
Li, M., Dalakas, M. C.
(2000). The muscle mitogen-activated protein kinase is altered in sporadic inclusion body myositis. Neurology
54: 1665-1670
[Abstract][Full Text]
Stelow, E. B., Johari, V. P., Smith, S. A., Crosson, J. T., Apple, F. S.
(2000). Propofol-associated Rhabdomyolysis with Cardiac Involvement in Adults: Chemical and Anatomic Findings. Clin. Chem.
46: 577-581
[Abstract][Full Text]
Kaplan, P. W., Kerr, D. A., Conwit, R. A.
(2000). Weak and Numb Feet in a Man With Knobby Hands. Arch Neurol
57: 271-271
[Full Text]
Gominak, S. C., Cros, D. P.
(1998). Case 13-1998- A 23-Year-Old Man with Progressive Weakness and Paresthesias. NEJM
338: 1212-1219
[Full Text]
Emmerson, B. T.
(1996). The Management of Gout. NEJM
334: 445-451
[Full Text]
Previous
